Edgar Filing: ENDO PHARMACEUTICALS HOLDINGS INC - Form 4

ENDO PHARMACEUTICALS HOLDINGS INC

Form 4

March 16, 2010

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Check this box

if no longer subject to Section 16. Form 4 or

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

Form 5 obligations may continue. See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person * **HYATT MICHAEL**

2. Issuer Name and Ticker or Trading

Symbol

ENDO PHARMACEUTICALS HOLDINGS INC [ENDP]

3. Date of Earliest Transaction

(Month/Day/Year)

03/12/2010

5. Relationship of Reporting Person(s) to

OMB

Number:

Expires:

response...

OMB APPROVAL

Estimated average

burden hours per

3235-0287

January 31,

2005

0.5

Issuer

below)

(Check all applicable)

10% Owner

Other (specify

(First) 383 MADISON AVENUE, 43RD

FLOOR

(Last)

(Street) 4. If Amendment, Date Original

(Middle)

Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)

_X__ Director

Officer (give title

X Form filed by One Reporting Person Form filed by More than One Reporting

NEW YORK, NY 10179

(City)	(State) (2	(Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned								
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired on(A) or Disposed of (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
			Code V	Amount	or (D)	Price	(Instr. 3 and 4)			
Common Stock, par value, \$.01 per share	03/12/2010		M	2,009	A	(1)	257,605	D		
Common Stock, par value, \$.01 per share	03/12/2010		M	1,371	A	<u>(2)</u>	257,605	D		
Common Stock, par value, \$.01	03/16/2010		G	10,000 (3)	D	<u>(4)</u>	247,605 (5)	D		

Edgar Filing: ENDO PHARMACEUTICALS HOLDINGS INC - Form 4

per share

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	e 3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amor Underlying Secur (Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Am or Nu of Sha
2007 Stock Incentive Plan Restricted Stock Units (RSU)	<u>(6)</u>	03/12/2010		М		2,009	03/12/2010	03/12/2010 <u>(7)</u>	Common Stock	2,
2007 Stock Incentive Plan Restricted Stock Units (RSU)	<u>(6)</u>	03/12/2010		М		1,371	03/12/2010	03/12/2010 <u>(8)</u>	Common Stock	1,
2007 Stock Incentive Plan Restricted Stock Units (RSU)	(6)	03/12/2010		A	2,834		<u>(9)</u>	03/12/2012(9)	Common Stock	2,
2007 Stock Incentive	\$ 23.82	03/12/2010		A	8,094		(12)	03/12/2020	Common Stock	8,

Plan Stock Options

Reporting Owners

Reporting Owner Name / Address

Director 10% Owner Officer Other

HYATT MICHAEL

383 MADISON AVENUE

43RD FLOOR

NEW YORK, NY 10179

Signatures

/s/ Caroline B. Manogue, by Power of Attorney

03/16/2010

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This represents vesting of restricted stock units granted to Mr. Hyatt on March 12, 2009. Upon each vesting date, each vested restricted stock unit automatically converts into one (1) share of common stock of Endo Pharmaceuticals Holdings Inc.
- This represents vesting of restricted stock units granted to Mr. Hyatt on March 12, 2008. Upon each vesting date, each vested restricted stock unit automatically converts into one (1) share of common stock of Endo Pharmaceuticals Holdings Inc.
- (3) These shares were gifted by Mr. Hyatt to a 505(c)(3) nonprofit organization and he received no consideration therefor.
- (4) These shares were gifted by Mr. Hyatt, and therefore, he did not receive any consideration therefor.
 - This number represents (i) 215,000 shares of common stock owned directly by Mr. Hyatt, (ii) 20,750 shares of common stock held in trusts for which Mr. Hyatt serves as trustee and as to which shares Mr. Hyatt holds either the sole or the shared power of disposition and power to vote, (iii) 2,262 shares of restricted stock, all of which are fully vested and (iv) 9,593 restricted stock units (including the 2,834
- (5) restricted stock units reported in Table II), 4,750 of which are fully vested. Mr. Hyatt's beneficial ownership disclosed in this table excludes all shares held by Mr. Hyatt indirectly, including shares underlying stock options as well as a total of 25,000 shares of common stock held in trusts for the benefit of Mr. Hyatt's adult children, as to which shares Mr. Hyatt has neither the power of disposition nor the power to vote.
- (6) Upon each vesting date, each vested restricted stock unit automatically converts into one (1) share of common stock of Endo Pharmaceuticals Holdings Inc.
- Fifty percent (50%) of Mr. Hyatt's March 12, 2009 grant of restricted stock units (RSUs) generally vest on each of March 12, 2010 and March 12, 2011. The 2,009 shown here is the amount that vested on March 12, 2010. Upon vesting, we consider the underlying RSUs to be expired.
- Fifty percent (50%) of Mr. Hyatt's March 12, 2008 grant of restricted stock units (RSUs) generally vest 50% on each of March 12, 2009 and March 12, 2010. The 1,371 shown here is the amount that vested on March 12, 2010. Upon vesting, we consider the underlying RSUs to be expired.
- (9) These restricted stock units (RSUs) generally vest 50% per year on each of March 12, 2011 and March 12, 2012. Upon vesting, we consider the underlying RSUs to be expired.
- (10) These securities were granted to Mr. Hyatt in consideration of his services on the Endo Pharmaceuticals Holdings Inc. Board of Directors.
- (11) Representing the right to buy shares of common stock, par value \$0.01 per share, of Endo Pharmaceuticals Holdings Inc.

Reporting Owners 3

Edgar Filing: ENDO PHARMACEUTICALS HOLDINGS INC - Form 4

(12) These stock options are generally exercisable 25% per year on each of March 12, 2011, March 12, 2012, March 12, 2013 and March 12, 2014.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.